Venetoclax (ABT-199) is a potent, selective, and orally bioavailable Bcl-2 inhibitor (Ki < 0.01 nM). It induces autophagy and inhibits Bcl-2-dependent cell growth and tumor xenografts. Venetoclax has shown antileukemic activity in refractory chronic lymphocytic leukemia and other Bcl-2-dependent cancers. Reagent grade, for research purpose.
Usually ships within 24 hours.